Linn Energy LLC (NASDAQ:LINE) is down 16% in pre-market trading due to falling oil prices resulting from yesterday’s world oil producers meeting in Doha, excluding Iran. Brent crude oil fell 7% to $41.23 a barrel while U.S. crude oil fell 7% to $38.48 a barrel. Investors were hoping for an agreement to freeze oil production in the meeting in order to stabilize falling prices, as Saudi Arabia indicated they were open to such an agreement pending all Opec members complied.  However, Iran’s repeated stance on refusing to freeze production, as well as its absence from the meeting, failed to produce any meaningful action in Doha. Following the meeting, Qatar’s energy minister Mohammad bin Saleh al-Sada stated, “We of course respect [Iran’s] position… The freeze could be more effective definitely if major producers, be it from Opec members like Iran and others, as well as non-Opec members, are included in the freeze.”

According to TipRanks’ statistics, 100% of analysts who have rated the company in the past 3 months are bearish on the stock. The average 12-month price target for the stock is $0.50, marking a 25% upside from where shares last closed.

Relypsa Inc (NASDAQ:RLYP) is down over 5% in pre-market trading after financial blogger George Rho of Seeking Alpha commented negatively on the stock, particularly focusing on the company’s only FDA-approved drug Veltassa, intended to treat hyperkalemia. The blogger first mentions that the Boxed Warning on Veltassa, where certain drugs will interact negatively if taken too closely, is likely to have doctors prescribe a competitor AstraZeneca’s ZS-9. According to Rho, ZS-9 is on its way to approval within the next 6 weeks. Moreover, Rho points to clinical data which indicated ZS-9 is the better of the two at treating hyperkalemia. While Rho acknowledges that analysts have positive revenue projections for Veltessa, he notes that analysts can only predict the future behavior of stock, not a drug, and “ted to be an optimistic lot”.

According to TipRanks, George Rho has a 63% success rate recommending stocks with a 1.2% average return per recommendation.George Rho Stats

Chiasma Inc (NASDAQ:CHMA) is down a staggering 55% in pre-market trading after the FDA issued a Complete Response Letter indicating that the company’s NDA for Mycappsa was not sufficient for approval. Mycappsa is intended to treat adults with acromegaly, a growth disorder. The FDA noted that Chiasma would have to conduct an additional clinical trial, as its current NDA did not provide adequate efficacy for FDA approval. Following the letter, Chief Executive Mark Leuchtenberger stated, “We are surprised, disappointed and respectfully disagree with the FDA’s decision.” He continued, “The FDA has encouraged us to request an end of review meeting with the agency to discuss the path forward, and we will do so.”

According to TipRanks, 100% of analysts who have rated the stock in the past 3 months are bullish. The average 12-month price target for the stock is $24.50, marking a 141% upside from where shares last closed.

Loxo Oncology Inc (NASDAQ:LOXO) is up 8% in pre-market trading after the company released positive results from its phase 1 trial of Loxo-1010, a selective TRK inhibitor intended for tumor regression. The company reported that 6 out of the 7 patients enrolled in the study demonstrated significant tumor regressions, with the seventh remaining on the study until the cutoff date. LOXXO-101 was able to cause tumor regressions in different types of cancers such as sarcoma, gastrointestinal stromal tumor, thyroid cancer, and more. The company plans to host an investor conference call today at 8:00 a.m. ET.

According to TipRanks, only one analyst rated the company in the past 3 months with a Buy rating and $25 price target, marking a 3% downside from where shares last closed.

StemCells Inc (NASDAQ:STEM) is soaring more than 20% in pre-market trading today up to $0.28 as the biotech company presented positive data this morning. At the 2016 American Spinal Injury Association (ASIA), the company announced data from the ongoing Phase II trial of HuCNS-SC cells in the treatment of chronic spinal cord injuries. The company explained that so far, five of six patients enrolled in the study after six months displayed improved muscle strength, with four of these five patients displaying improved fine motor skills. Management stated that the final results for these six patients will be released later this quarter.

According to TipRanks, both analysts who have weighed in on the company in the last 3 months are bullish on the stock with an average 12-month price target of $1.75, marking an overwhelming 660% potential upside from where shares last closed.